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doi:10.1016/j.jtcvs.2004.05.025346 The Journal of Thoracic and CardioIt has been estimated that 173,770 new lung cancers will be diagnosed in theUSA in 2004, and 80,600 (46.3%) will be diagnosed in women. It has alsobeen estimated that 68,510 women will die of lung cancer in 2004, whichrepresents a 4.2% increase from 2001, when lung cancer took the lives of65,606 women. Lung cancer currently accounts for 12.7% of all cancersdiagnosed in the United States and for 28.5% of all cancer deaths.1 In 1987,
lung cancer surpassed breast cancer to become the leading cause of cancer death
among women. In fact, lung cancer now kills more women annually than breast,
uterine, and ovarian cancers combined. Unfortunately, women have come a long
way, but not along a good path. Between 1950 and 1994, female lung cancer
mortality increased 500%, from 3% to 22%.2 In 1965, approximately 30,000 US
women died of 10 categories of tobacco-related illnesses, but by 1985 that figure had
risen to 106,000.3 That tobacco-related diseases including lung cancer are an
increasingly major health problem for women is undeniable.
Smoking Patterns in Women and Men
The lung cancer epidemic began later among women than among men, in large part
because of differences in cigarette smoking patterns. Smoking prevalence among
women was 18.1% in 1935, peaked at 33.3% in 1965, and stayed at that level
through the late 1970s. Since that time, the rate has declined slowly to its current
level of 23.5%.4 Unfortunately, women are beginning to smoke at a younger age,
owing in large part to successful tobacco advertising campaigns directed toward
both adolescents and women. The smoking rate among female high school students,
for example, increased from 17.9% in 1991 to 23.5% in 1997 and had climbed to
27.7% by 2001.5 Because of the latency between exposure to tobacco and tobacco
smoke carcinogens and the development of lung cancer, the ill effects of tobacco
will be with us for many decades.
Lung cancer incidence among men is declining at a faster rate than among
women, chiefly because of the decrease in smoking prevalence among men. In the
last decade, the incidence of lung cancer among men declined by 2.2% from the
previous decade, whereas the incidence of lung cancer among women increased by
0.5% during the same time period. Table 1 illustrates the trends in lung cancer
incidence during the last 3 decades.
Lung Cancer Susceptibility
More than 85% of all patients with lung cancer have a cigarette smoking history, yet
only 20% of smokers acquire lung cancer. This suggests that factors other than
smoking predispose an individual toward development of lung cancer. Factors that
have been implicated include sex, genetic alterations, second-hand smoke, occupa-
tional exposure (eg, asbestos), diet, chronic obstructive pulmonary disease, and
previous tobacco-associated cancer. Lung cancer incidence among women exceeds
that expected from smoking prevalence alone, which raises the question of women’s
increased susceptibility to this disease.6 Several studies have suggested that women
may be more susceptible than men to the ill effects of the carcinogens in tobacco and
tobacco smoke.6-11 Women with lung cancer have been consistently shown to (1)
have smoked less on average (31 vs 52 pack-years), (2) be younger, (3) be 2 to 3
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Ltimes more likely to have never smoked, and (4) get ade-
nocarcinoma more often than their male counterparts.
Women were also found to have started smoking at a later
age, to smoke brands with lower tar content, and to inhale
less deeply than men in a study by Zang and Wynder.8
Despite these findings, women had 1.2- to 1.7-fold higher
odds of getting lung cancer than men at every level of
exposure to cigarette smoke in that study. Although this
finding has been confirmed by others,9 it has not been
corroborated by all studies.12,13
Biologic Differences
Reasons offered to help explain these findings include (1)
differences in nicotine metabolism, (2) differences in the
cytochrome P-450 enzyme system that activates and detoxi-
fies tobacco and tobacco smoke carcinogens, (3) differences
in DNA adduct levels and an individual’s ability to repair
damaged DNA, and (4) hormonal effects. It has been sug-
gested that women have reduced plasma clearance of nico-
tine and its metabolites and that these products may be the
precursors of tobacco-specific carcinogens.14,15 It has also
been hypothesized that an individual’s ability to activate
and detoxify tobacco and tobacco smoke carcinogens and to
repair damaged DNA modulates his or her risk of lung
cancer.16 The schema in Figure 1, adapted from Hecht,17
has been proposed to help explain the reasons for differ-
ences in lung cancer susceptibility.
Polycyclic aromatic hydrocarbons and nitrosamines are
both present in tobacco smoke and exert their effects
through both gene mutations and the formation of DNA
adducts in target tissues such as the lung.18,19 It has been
shown that women with lung cancer have gene polymor-
phisms in the cytochrome P-450 enzymes (CYP1A1,
CYP1A2, and CYP3A4) that result in an increased level of
DNA adducts and thus a decreased ability to detoxify to-
bacco carcinogens.20 High levels of DNA adducts are be-
lieved to play a role in the initiation of carcinogenesis.21
Women with the CYP1A1 mutation had a higher lung cancer
risk than men (odds ratio 4.98 vs 1.37). Women with both
CYP1A1 and GSTM1 mutations had a higher lung cancer
risk than men (odds ratio 6.54 vs 2.36). Furthermore,
women with lung cancer had higher incidences of both
CYP1A1 and GSTM1 mutations than did women without
lung cancer.22,23
It has been found that DNA adduct levels are higher
among women with lung cancer than among their male
counterparts after adjustment for smoking dose. This sug-
gests that women are exposed to higher levels of tobacco
carcinogens than men and may thus have a higher relative
risk than men of tobacco-induced lung cancer.20,22-23 A
reduced capacity to repair damaged DNA has also been
associated with an increased risk of lung cancer, and women
The Journal of Thoracihave been found to have a lower capacity than men for
DNA repair.22
Hormonal Differences
The role of hormones, estrogen in particular, as a risk factor
for the development of lung cancer is another area of
vigorous investigation. Estrogen is known to be a risk factor
for the development of adenocarcinoma of the breast, ovary,
and endometrium, and lung adenocarcinoma is known to be
more common among women than men. Non–small cell
lung cancer lines (both squamous cell and adenocarcinoma)
have been found to express estrogen receptors.24,25 Estrogen
may be involved in lung carcinogenesis by activating cell
proliferation through an indirect action on lung fibroblasts
or by metabolic activation to intermediates that produce
DNA adducts and cause oxidative damage.24
Further observations that support a role for estrogen in
the development of lung adenocarcinoma include the fol-
lowing: (1) Early age (40 years) at menopause is associ-
ated with a decreased risk of lung adenocarcinoma (odds
ratio 0.3). (2) Estrogen replacement therapy is associated
with an increased risk of lung adenocarcinoma (odds ratio
1.7); however, in that study no adjustment was made for the
amount of smoking. (3) A positive interaction of estrogen,
smoking, and lung adenocarcinoma has been found (odds
ratio 32.4).26 In addition, Zang and Wynder8 found that
women older than 55 years with lung cancer (particularly
adenocarcinoma) were nearly twice as likely as younger
women with lung cancer to have never smoked. No similar
age-related difference was found among men with lung
cancer or among female control subjects.
Genetic Differences
There is a higher frequency of p53 tumor suppressor gene
mutations among women with non–small cell lung cancer
than among men with non–small cell lung cancer. There is
also a higher DNA adduct level in normal lung tissue in
women with lung cancer, which supports the contention that
p53 mutations might be responsible in part for higher DNA
adduct levels.27 It has been found that the frequency of
nucleotide transversions at the p53 locus is higher among
female smokers with lung cancer than among either male
smokers with lung cancer or female never-smokers with
lung cancer.28,29
K-ras gene mutations have also been found more com-
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Lwere smokers than among male smokers with lung cancer
(17.4%). The presence of K-ras mutation has been found to
predict a poor prognosis. It has been found mainly in
adenocarcinomas of the lung and only in patients with lung
cancer who also have a history of smoking.30 This obser-
vation has led Nelson and colleagues30 to propose that
“cigarette smoking induces K-ras mutations and the result-
ant clones are further expanded by a second event that may
involve the growth-promoting effects of hormones (like
estrogen) that may be specific for the adenocarcinoma his-
tology.”
Another area of investigation involves genetic differ-
ences in the gastrin-releasing peptide receptor (GRPR) gene
that is located on the X chromosome. The peptide plays a
role in carcinogenesis by stimulating cell proliferation.31
Shriver and colleagues32 found that GRPR messenger RNA
was detected more frequently in female than male nonsmok-
ers (55% vs 0%) and that among smokers GRPR messenger
RNA was detected at lower levels of tobacco exposure in
women than in men (75% vs 20%). The authors concluded
that the presence of two copies of the GRPR gene in women
might play a role in their increased susceptibility to lung
cancer. They also considered that GRPR expression in the
airway, either de novo or as a result of exposure to tobacco,
might predispose an individual toward the development of
lung cancer.32
In summary, complex interactions of tobacco, tobacco
smoke carcinogens, and biologic, hormonal, and genetic
factors probably explain the differences in lung cancer risk
between women and men. The precise nature of these in-
teractions is the focus of ongoing investigations.
Histologic Differences in Lung Cancer Between
Men and Women
In recent years, the histologic distribution of lung cancer has
changed in both sexes. Four separate studies that used data
from large cancer registries have demonstrated an overall
decrease in the incidence of squamous cell carcinoma and
an increase in the incidence of adenocarcinoma.33-36 The
histologic distribution of lung cancer among women is
Figure 1. Schema depicting individual differences in
carbons. (Adapted from Hecht SS. Tobacco smoke carc
210. Published with permission of Oxford University Pdistinctly different from that among men. Most nonsmokers
348 The Journal of Thoracic and Cardiovascular Surgery ● Septand never-smokers with lung cancer are female, and ade-
nocarcinoma prevails in these groups.
Like men, most women who acquire lung cancer are
current or former smokers. The incidence of squamous cell
cancer is lower among women than among men, ranging
from 10% to 35% among women versus 30% to 55% among
men.37-40 Small cell carcinoma histologic type accounts for
17% to 34% of lung cancers among women, in contrast to
15% to 20% among men. The percentage of lung adenocar-
cinomas among women has been higher than that among
men since the 1960s and averages between 20% and 60% in
reported series.8-10, 34,37-45 The incidence of adenocarci-
noma among women who are nonsmokers is even high-
er.38,46 The bronchoalveolar subtype of adenocarcinoma is 2
to 4 times more common among women with lung cancer,
particularly women who are nonsmokers, than among men
and constitutes 3.6% of the cases in most series.8,37,47,48
The increased incidence of adenocarcinoma, as opposed
to other histologic types of lung cancer, among women has
been attributed to several causes, including biologic factors,
such as hormones, enzyme phenotypes, and underlying lung
disease, and environmental factors, such as second-hand
smoke, to which women are more often exposed.34,46, 49-52
For example, Adami and colleagues50 demonstrated a 30%
increase in lung cancer among women receiving estrogen
replacement therapy. The predominance of adenocarcinoma
is particularly striking among nonsmokers, among whom
the incidence ranges from 50% to 93%.38,43,46,51 Among
nonsmokers with lung cancer, women outnumber men
nearly 3:1 a fact that strongly supports a sex-based differ-
ence in the susceptibility toward the development of lung
cancer, particularly adenocarcinoma of the lung.
Sex-Based Differences in Prognosis and Outcome
A retrospective study by Ferguson and associates53 of 478
men and 294 women with lung cancer demonstrated that the
vast majority of patients are seen with advanced disease.
Compared with men, however, a higher percentage of
women were first seen with stage I disease (16.3% vs 9.4%),
whereas fewer had stage III disease (35.4% vs 44.4%).
nse to carcinogens. PAH, Polycyclic aromatic hydro-
ens and lung cancer. J Natl Cancer Inst. 1999;91:1194-
)respo
inogEqual percentages of men and women were first seen with
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Lstage II (4.4% vs 5.2%) and stage IV (43.9% vs 41%)
disease. A larger database analysis has suggested that stage
I disease may be more equally distributed between men and
women, but the fact remains that the majority of both men
and women still are first seen with stage III or stage IV
disease.37
Several studies, including an analysis of 1521 patients
treated for small cell lung cancer in several Cancer and
Leukemia Group B trials, have demonstrated that stage for
stage, women exhibit better survival than do men.54-57
These studies also found that women tended to be seen with
later stage disease, regardless of age, performance status,
and whether they were enrolled in clinical trials.55 In the
Southwest Oncology Group Study 8269 of limited stage
small cell lung cancer, female sex was found to be a strong
favorable independent predictor of survival in the univariate
analysis. Five-year survival rates for women were 37%,
compared with 19% for men. However, female sex was not
found to be a significant predictor of survival in the multi-
variate analysis.58
Several studies have shown improved survival for
women treated for lung cancer.38,59-62 The 5-year survival is
15.6% for women, compared with 12.4% for men.61 It is of
interest that a recent study by Minami and colleagues38
demonstrated that complete surgical resection was possible
in women less often than in men because of increased
incidence of malignant pleural effusion and T4 disease
(19.9% vs 14.4%). In cases of surgically resectable disease,
however, survival after complete resection, especially for
women older than 60 years, was markedly improved relative
to their male counterparts. Much of the increase in survival
is likely attributable to an increased life expectancy of
women relative to men in this age group. When complete
resection, greater life expectancy, and better performance
status were all taken into consideration, women were found
to have a 2-fold increased chance of long-term survival.63 In
advanced non–small cell lung cancer a significant benefit
was also seen, whereby the 2-year survival rate was more
than doubled from 11% in men to 27% in women.64 Im-
proved survival for women in every stage was shown in a
retrospective cohort study of 104 men and women.65
Women lived an average of 12 months longer than men,
even though equal numbers of stage I disease were present
in both groups and more stage IV disease was present
among the women. Overall, nearly all clinical studies per-
formed that have focused on survival in women with lung
cancer have found the female sex to be at least a positive or
neutral prognostic factor. The dichotomy of lung cancer in
women, as predominantly stage I or disseminated stage IV
disease, has resulted in the appearance of equal survivals of
men and women overall when in fact survival is improved
among women when adjusted for the clinical stage of dis-
ease. This improved survival according to clinical stage was
The Journal of Thoracidemonstrated in a small cohort study by Ouellette and
associates65 as well as a large population-based study from
Poland37 that analyzed more than 20,000 cases of lung
cancer, of which nearly 3000 cases were in women. In this
study,37 female sex was a positive prognostic variable in
both univariate and multivariate analyses, behind clinical
stage and performance status in terms of importance and
clinical impact. That the survival benefit of female sex
remains even when these other prognostic factors are taken
into account suggests that the evaluation of disease-free
survival and hormonal status will be important parameters
to include in future sex-based clinical studies.
Conclusion
Evidence is accumulating to support the notion that the risk
of development of lung cancer is different among women
than among men. Women may be more susceptible to the ill
effects of carcinogens in tobacco and tobacco smoke as a
result of hormonal, genetic, and metabolic differences be-
tween the sexes. The preponderance of adenocarcinoma
among women compared with men, and among women who
are nonsmokers as well as younger women, argues in favor
of a hormonal influence in this subtype of lung cancer.
Future research efforts will continue to investigate and
corroborate the findings outlined in this editorial and it is
hoped will lead to a better understanding of lung cancer in
both women and men.
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